Bicycle Therapeutics (FRA:50BA) Total Debt per Share: €0.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:50BA Bicycle Therapeutics PLC FRA:50BA
60 GF Score
Price €3.36
GF Value €15.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Total Debt per Share?

Bicycle Therapeutics FRA:50BA +2.44% 60 Total Debt per Share is €0.18 as of Jun. 2026. GuruFocus rates FRA:50BA with a GF Score™ of 60/100 and a GF Value™ of €15.18 (Possible Value Trap). The stock has 5 warning signs investors should review.

€0.18 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Bicycle Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 was €0.18.

Bicycle Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Bicycle Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicycle Therapeutics Total Debt per Share Chart

Bicycle Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only 1.33 1.40 0.97 0.13 0.21

Bicycle Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.07 0.21 0.19 0.18
FRA:50BA
60GF Score
Bicycle Therapeutics PLC FRA:50BA
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicycle Therapeutics Total Debt per Share Calculation

Bicycle Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.04+2.35)/69.37
=0.21

Bicycle Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(11.87+0.85)/69.81
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.18 mean?
Bicycle Therapeutics (FRA:50BA) has a Total Debt per Share of €0.18 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Bicycle Therapeutics and its competitors.
Is Bicycle Therapeutics' Total Debt per Share too high?
Bicycle Therapeutics' current Total Debt per Share is €0.18. Overall, Bicycle Therapeutics has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Total Debt per Share compare to CYDY and ALXO?
Bicycle Therapeutics' Total Debt per Share of €0.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Bicycle Therapeutics and its competitors. Bicycle Therapeutics's current Total Debt per Share is €0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €15.18, compared to a current price of €3.36 — trading 77.9% below its estimated fair value. The current Total Debt per Share is €0.18. Bicycle Therapeutics' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Total Debt per Share is €0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.36 is trading 77.9% below its estimated GF Value™ of €15.18. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • Total Debt per Share: €0.18
  • GF Value™: €15.18 vs. price of €3.36 (77.9% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
60GF Score

Get the complete analysis for FRA:50BA

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.36
Price
€15.18
GF Value